We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
+6.3%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$183M
AUM Growth
-$3.29M
Cap. Flow
-$8.86M
Cap. Flow %
-4.83%
Top 10 Hldgs %
62.72%
Holding
56
New
18
Increased
15
Reduced
7
Closed
16
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
1.1 years

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
2 Industrials 2.88%
3 Miscellaneous 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
LKFT icon
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.18B
$20.6M 11.25%
465,000
+60,000
+15% +$2.52M
2021 Q1
7 quarters
PRTA icon
2
Prothena
PRTA
$422M
$19.9M 10.84%
330,000
+8,907
+3% +$522K
2020 Q3
9 quarters
KZR icon
3
DELISTED
Kezar Life Sciences
KZR
$12.4M 6.74%
175,443
+42,653
+32% +$3.16M
2021 Q1
7 quarters
MGTX icon
4
MeiraGTx Holdings
MGTX
$780M
$10.7M 5.81%
1,633,546
+530,181
+48% +$3.64M
2022 Q1
3 quarters
ALBO
5
DELISTED
Albireo Pharma Inc
ALBO
$10.5M 5.74%
486,726
-4,518
-0.9% -$95.5K
2018 Q3
17 quarters
HZNP
6
DELISTED
Horizon Therapeutics
HZNP
$10.2M 5.59%
90,000
-213,000
-70% -$17.7M
2022 Q3
1 quarter
ALKS icon
7
Alkermes
ALKS
$7.55B
$8.92M 4.87%
341,521
-160,629
-32% -$3.84M
2022 Q3
1 quarter
HUM icon
8
Humana
HUM
$46.8B
$8.84M 4.82%
17,253
+4,453
+35% +$2.34M
2022 Q3
1 quarter
ORIC icon
9
Oric Pharmaceuticals
ORIC
$765M
$6.95M 3.79%
1,180,000
+243,666
+26% +$823K
2022 Q3
1 quarter
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$6.28B
$6.02M 3.28%
308,776
+23,776
+8% +$470K
2022 Q1
3 quarters
ALDX icon
11
Aldeyra Therapeutics
ALDX
$50.7M
$5.98M 3.26%
858,709
-352,091
-29% -$2.01M
2018 Q4
16 quarters
TNET icon
12
TriNet
TNET
$2.89B
$5.29M 2.88%
+78,000
New +$5.38M
2022 Q4
0 quarters
CUE icon
13
Cue Biopharma
CUE
$34.7M
$5.25M 2.86%
61,350
+9,831
+19% +$899K
2019 Q4
12 quarters
STTK icon
14
Shattuck Labs
STTK
$454M
$4.86M 2.65%
2,113,493
+992,717
+89% +$2.49M
2021 Q3
5 quarters
OPCH icon
15
Option Care Health
OPCH
$4.73B
$4.66M 2.54%
+154,898
New +$4.81M
2022 Q4
0 quarters
QDEL icon
16
QuidelOrtho
QDEL
$571M
$4.28M 2.34%
50,000
-12,900
-21% -$1.09M
2022 Q1
3 quarters
KALV icon
17
DELISTED
KalVista Pharmaceuticals
KALV
$4.2M 2.29%
621,667
+91,605
+17% +$491K
2021 Q2
6 quarters
HCAT icon
18
Health Catalyst
HCAT
$100M
$3.7M 2.02%
+347,724
New +$3.36M
2022 Q4
0 quarters
ABCL icon
19
AbCellera Biologics
ABCL
$3.16B
$3.27M 1.78%
322,754
+236,250
+273% +$2.73M
2022 Q3
1 quarter
LENZ icon
20
LENZ Therapeutics
LENZ
$93M
$3.04M 1.66%
130,937
+80,016
+157% +$1.85M
2022 Q3
1 quarter
UNH icon
21
UnitedHealth
UNH
$305B
$2.65M 1.45%
+5,000
New +$2.65M
2022 Q4
0 quarters
NTLA icon
22
Intellia Therapeutics
NTLA
$1.4B
$2.52M 1.37%
+72,116
New +$3.43M
2022 Q4
0 quarters
CSII
23
DELISTED
Cardiovascular Systems
CSII
$1.99M 1.08%
+145,916
New +$2.03M
2022 Q4
0 quarters
OSH
24
DELISTED
Oak Street Health
OSH
$1.81M 0.99%
+84,000
New +$1.76M
2022 Q4
0 quarters
ADCT icon
25
ADC Therapeutics
ADCT
$180M
$1.78M 0.97%
463,310
+215,680
+87% +$862K
2022 Q3
1 quarter

Similar funds

Prosight Management's Q4 2022 Portfolio in Review

As of Q4 2022, Prosight Management held 56 positions worth $183M, down 1.8% from $187M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management withdrew a net $8.86M in Q4 2022, closing 16 positions and reducing 7 holdings. Its most notable exit was Charles River Laboratories, an estimated $6.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Industrials and Miscellaneous.

Against the trend, Prosight Management opened a new position in TriNet worth $5.29M.

  • Prosight Management's largest Q4 2022 buy was TriNet: 78,000 shares worth $5.29M.
  • Prosight Management added most to MeiraGTx Holdings in Q4 2022, an estimated $3.64M increase.
  • Prosight Management's biggest Q4 2022 reduction was Horizon Therapeutics, cutting an estimated $17.7M.
  • Prosight Management fully exited Charles River Laboratories in Q4 2022, selling an estimated $6.54M.
  • Prosight Management's ten largest holdings make up 63% of its $183M portfolio in Q4 2022.
  • Prosight Management opened 18 new positions and closed 16 in Q4 2022.
  • Prosight Management's portfolio value fell 1.8% quarter-over-quarter to $183M.

Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.